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Background. In stressful situations, decision making processes related to informed consent may be compromised. Given the
profound levels of distress that surrogates of children in pediatric intensive care units (PICU) experience, it is important to
understand what factors may be influencing the decision making process beyond the informed consent. The purpose of this study
was to evaluate the role of clinician influence and other factors on decision making regarding participation in a randomized clinical
trial (RCT). Method. Participants were 76 children under sedation in a PICU and their surrogate decision makers. Measures included
the Post Decision Clinician Survey, observer checklist, and post-decision interview. Results. Age of the pediatric patient was related
to participation decisions in the RCT such that older children were more likely to be enrolled. Mentioning the sponsoring institution
was associated with declining to participate in the RCT. Type of health care provider and overt recommendations to participate
were not related to enrollment. Conclusion. Decisions to participate in research by surrogates of children in the PICU appear to
relate to child demographics and subtleties in communication; however, no modifiable characteristics were related to increased
participation, indicating that the informed consent process may not be compromised in this population.

1. Introduction
Obtaining informed consent prior to subject participation
in an experimental protocol is vital to maintain ethical
standards and ensure respect for persons. Even with a number of national and international guidelines to ensure true
informed consent [1–5], some in the field believe the concept
is an elusive ideal [6]. Patients who participated in clinical
trials were unaware of the particulars of the research (e.g.,
randomization, treatment arms, etc.) or that the treatment
was experimental in nature [7–9], and information presented
in the consent form was not always taken into account
when making medical decisions [10]. Moreover, for nearly
two-thirds of those approached for study participation, the
consent form played no part in their participation decision
[10].

Problems with comprehension and readability [11], a
misconception of direct therapeutic benefit [9, 12], and not
recognizing the ability to discontinue [9] or opt out of
treatment [13] also impede the function of the informed
consent process. Importantly, the decision making process
involving informed consent may be flawed, especially in high
pressure environments [14]. Given the profound and sometimes clinical levels of distress that surrogates (i.e., parents
or legal guardians) of children in pediatric intensive care
units (PICU) experience [15], it is important to understand
what factors may be influencing the decision making process
beyond the informed consent process. Properly addressing
such factors would help protect the integrity of the informed
consent process.
Although the informed consent process precludes coercion and denial of services, it may nevertheless be challenging
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for physicians (i.e., medical doctors) to fully disengage
from the role of health care provider during the informed
consent process. Physicians have significant influence on
medical decisions that are made by their patients [16–18], and
communication with the physician during clinical encounters
is an important factor in the final decision to participate
in clinical trials [19–21]. In a study involving oncology
patients, 68% of the time physicians recommended that their
patients participate in a clinical trial, which was related to
the resultant decision to participate [22]. Surrogates often rely
on their child’s physicians for their knowledge and expertise
in the medical care of their child [16, 17]. Therefore, it is
hypothesized that treating physicians play a significant role
in the decisions that surrogates make regarding research trial
participation. Based on previous findings [23], it is expected
that physicians recommending these research opportunities
have a significant influence on their patients’ decisions to
participate in clinical trials.
The PICU is a multidisciplinary environment, and
although the patient’s physician may present trial information
to eligible study participants, other health care providers
(e.g., nurses and respiratory therapists) may also serve in
this role. Clinician understanding and actual or perceived
endorsement of the trial being presented [24, 25] and potential benefits to the patient are associated with participation
decisions [24]. A personal physician may be more apt to
handle these types of questions depending on the type of
study and clinician training [24], and it is possible that a
physician’s explanation may have a stronger impact on decision to participate than another health care provider (HCP).
Lastly, distrust of sponsoring institutions has been noted as a
reason for declining participation in research studies [3, 26].
Therefore, mention of the sponsoring institution to potential
participants will also be examined as a potential factor in the
surrogate decision-making process.
This study provides insight into how influential physician
recommendations are in this unique population of surrogate
decision makers for critically ill children in potentially life
threatening situations. It also provides insight into the role
of different HCPs and additional putative factors in the
decision-making process. There are three primary hypotheses. First, it is expected that a HCP’s overt recommendation
to participate in the RCT will be related to participation
decisions such that surrogates will be more likely to enroll
their child into the RCT. Second, it is expected that surrogates
receiving RCT information from a physician will be more
likely to enroll their child in the RCT than those receiving
the information from another HCP. Third, it is expected that
surrogates who are given information about the institution
supporting the RCT will be more likely to enroll their child
in the protocol than those not receiving this information.

2. Method
2.1. Participants. Participants were recruited from Rainbow
Babies and Children’s Hospital Pediatric Intensive Care Unit.
Data were collected from a total of 76 surrogate decision makers of hospitalized children in the PICU, with each surrogate

International Journal of Pediatrics
Table 1: Demographics.
Variable

𝑛

%

Female surrogate
Male pediatric Patient
Surrogate race
Caucasian
African American
Other
Single parent Household
12 or fewer years Surrogate
education
Income above 25 K Annually

70
44

92.0
57.1

28
44
4
35

36.8
57.9
5.3
48.7

31

41.9

40

49.3

Variable

Mean

SD

Range

Age of pediatric Patient (years)
Age of surrogate (years)

5.76
32.13

4.84
8.02

0–17
17–59

representing one pediatric case (see Table 1). Hospitalized
children had suffered a wide range of illnesses and accidents
and were all in need of mechanical ventilation for at least a
24-hour period.
2.2. Procedure. This study was part of a larger study on
informed consent. On call research nurses were contacted
once a child became eligible to participate in a greater than
minimal risk phase III clinical trial. This individual first
provided an explanation of the present study on informed
consent and obtained written informed consent. Surrogates
then participated in an informed consent conference regarding participation in a drug RCT with their child’s HCP. In this
conference, the HCP presented an opportunity to participate
in a clinical trial to test the efficacy of an experimental
pharmaceutical treatment. Randomization procedures were
explained, safety concerns addressed, and voluntary participation stressed. If the surrogates expressed an interest in
enrolling their child, they were given a consent form to
read and provided written informed consent for the drug
RCT. Some HCPs presenting trial information were study
investigators and others were not. HCP involvement in the
RCT presented was controlled for in study analyses. Conferences with surrogates were observed and audio-recorded
by research assistants. Following this conference, surrogates
participated in a private structured interview about this HCP
interaction. Both the drug RCT and the current informed
consent study were approved by University Internal Review
Boards.
2.3. Measures
2.3.1. Semistructured Post-Decision Interview. A brief interview was conducted with the surrogates after they finished the
informed consent conference. The interview was conducted
in private, without the child’s HCP present. The purpose of
this interview was to obtain participant specific characteristics and to assess understanding of the clinical trial and treatment options. Participant specific characteristics included
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Table 2: Demographic factors associated with decision to participate in the RCT.
Variable
Surrogate gender
Surrogate race
Marital status
Surrogate Education level
Income level
Surrogate age
Pediatric patient age

𝜒2
.03
.001
2.27
3.04
2.23

df
1
1
2
2
4

𝑃
>.05
>.05
>.05
>.05
>.05

𝑡

df

𝑃

.80
3.00

20.09
22.30

>.05
<.005∗

Note: df = degrees of freedom, ∗ significant.

decision making preferences, risk taking inclinations, quality
of relationship with their HCP, subject assessment of treatment risks and benefits, comprehension of trial participation
requirements, their final decision regarding participation in
the clinical trial, and the rationale behind their decision.
2.3.2. Post-Decision Clinician Survey. The HCP that participated in the informed consent conference completed a survey
after the informed consent conference. This measure was
used to gather information about the HCP and his or her level
of involvement in the randomized clinical trial. Demographic
data for the HCP was recorded and included type of HCP,
specialty, board certification, membership in clinical trials
groups, exposure to trials during training, whether or not the
HCP was an investigator in the drug trial, age, gender, and
race. The HCP also provided their perception of the strength
of their recommendation regarding participation in the RCT
and the likelihood of the patient to benefit from the clinical
trial.
2.3.3. The Observer Checklist. This instrument was developed for the current study and was used to document and
assess the interactions between surrogates and their child’s
HCP. The checklist was completed by research assistants
who observed the informed consent process; the audiotape
was used for coding purposes. The measure lists specific
information categories related to informed consent that were
dichotomously coded as occurring or not occurring. Examples of information coded included whether the informed
consent process included an explanation of risks, benefits,
funding, and alternatives. Content initiators were also coded
in relation to each topic area raised. Past studies achieved
between 88 and 93% agreement on this measure among
independent raters [14, 21], and the current study achieved
an interrater reliability within this range at approximately
90% agreement. The measure was developed and chosen
to capture unique aspects and interactions of the consent
process not addressed by previously validated measures.
2.4. Statistical Analyses. A series of Chi-square analyses and
𝑡-tests were conducted to identify demographic factors significantly associated with the decision to participate in the RCT.
Hierarchical logistic regression analyses were performed to
test the primary hypotheses. Demographic factors associated
with the decision to participate in the RCT were entered as

control variables in the first step of the regression analyses
followed by the specific research question (i.e., HCP’s verbal
recommendation to participate (coded as yes or no), HCP
presenting trial information (coded as physician or other), or
HCP mention of the sponsoring institution (coded as yes or
no)). Each regression was then compared to a constant-only
model to determine whether the proposed hypothesis was
statistically significant. Effect sizes were analyzed with Cox
and Snell 𝑅-square and Nagelkerke 𝑅-square. All analyses
were performed using the statistical package for the social
sciences (SPSS) version 16.0.

3. Results
Participation in the RCT was not associated with any surrogate level data (see Table 2). However, participation was
associated with patient age such that surrogates of older
children (𝑀AGE = 6.212) were more likely to consent to
participate than surrogates of younger children (𝑀AGE =
3.055). Patient age was controlled for in study analyses.
For the first hypothesis, it was hypothesized that if a
HCP gave a verbal statement to the surrogate decision maker
advocating enrollment in the RCT, the surrogate would be
more likely to enroll their child in the RCT. The model with
age and HCP recommendation was not statistically different
from the constant-only model, and the effect size of HCP
recommendation was small (see Table 3). Since the results
were contrary to previous findings, the model was evaluated
without controlling for the age of the pediatric patient. This
model was compared to a constant only model, and the results
were still not significant, 𝑋2 (1) = .14, 𝑃 > .05. The effect
size of physician recommendation was even smaller, with
Cox and Snell 𝑅-square = .002 and Nagelkerke 𝑅-square =
.003. However, a post hoc correlation was used to examine
the relationship between strength of HCP recommendation
and the decision to enroll in the RCT, and the results were
significant. The stronger the recommendation, the less likely
the surrogate was to enroll their child; 𝑟 = −.33, 𝑃 < .05.
For the second hypothesis, it was hypothesized that the
type of HCP presenting the trial to the surrogate decision
maker would predict trial participation such that those
receiving the information from a physician would be more
likely to participate than those being informed by another
type of HCP (e.g., nurse or respiratory therapist). The model
with age and the HCP presenting the trial was not statistically
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Table 3: 𝛽 Weights and Chi-Square Results for Logistic Regression Analysis.

Hypothesis
(1) Age of Pediatric Patient
HCP Recommendation
(2) Age of Pediatric Patient
Type of HCP Presenting
(3) Age of Pediatric Patient
Mention Sponsoring Institution

𝛽
−0.19
−0.001
−0.20
−0.40
−0.09
−2.30

𝜒2

𝑃

Cox & Snell 𝑅2

Nagelkerke 𝑅2

4.90

>.05

.06

.11

5.08

>.05

.07

.12

11.05

<.005∗

.14

.14

∗

Note: HCP = Health Care Provider, significant.

different from the constant-only model, and the effect size of
the HCP presenting the trial was small (see Table 3).
Lastly, it was hypothesized that if a clinician referenced
the name of the institution supporting the trial and indicated
that the study was approved by the institution’s Internal
Review Board, the surrogate would be more likely to enroll
their child in the experimental protocol. The model with age
and mention of the sponsoring institution was significantly
different from the constant-only model, and the effect size
of mentioning the sponsoring institution was moderate (see
Table 3). The change in odds associated with a one-unit
change in reference to the supporting institution was −2.30,
indicating that if the supporting institution was mentioned,
the surrogate was 2.30 times less likely to enroll their child in
the experimental protocol.

4. Discussion
The purpose of the current study was to elucidate factors
that influence surrogate decision makers in the PICU to
participate in RCTs. This is particularly important given
the informed consent process has previously been found to
be flawed, particularly in stressful environments [14]. It is
therefore important to understand what may be influencing
such decisions in this vulnerable population. Demographic
variables were analyzed as potential covariates and putative
factors predicting trial participation were analyzed including
explicit verbal recommendation by the HCP to participate,
the type of HCP presenting the trial, and HCP mention of the
institution supporting the trial. Results from the majority of
demographic variables were not significant; those who chose
to participate in the RCT were not significantly different from
those who elected standard treatment on most demographic
domains. However, age of the pediatric patient was related
to surrogates’ decisions to enroll their child in the RCT.
Surrogates who had an older child in the PICU were more
likely to enroll them in the RCT than those with a younger
child. A younger child in the PICU may be perceived as
more vulnerable and unable to handle treatment when little
is known about its safety and side effects. Younger children
generally are seen as more vulnerable and less able to handle
both adverse and normative events; however, this view may
or may not be well founded [27, 28]. Nevertheless, patient age
was controlled for in study analyses.

The relationship between an explicit HCP recommendation to participate in the RCT and the decision to participate
was not significant, which indicates that a HCP recommending participation in the RCT did not predict whether a
surrogate enrolled their child in the RCT. This was contrary
to previous research findings, so the analysis was repeated
without controlling for the age of the pediatric patient. The
model still did not achieve statistical significance after age
was excluded indicating that age of the pediatric patient was
not accounting for the nonsignificant relationship. A larger
sample size may be needed to detect a significant effect of
physician recommendation on participation. However, it is
possible that the levels of extreme stress that are unique to
this time pressured situation may affect decision making in a
manner differently than previously hypothesized, particularly
in this population of surrogates that has children with acute
complications of chronic conditions. Stress affects brain
regions that are responsible for complex cognitive processes
[29]. This potential change in cognitive functioning may
cause surrogate decision makers to make decisions regarding
clinical trial participation before the information is presented
to them. In fact, previous research has found that this decision
prior to information presentation is one of the strongest
predictors of participation [30]. This type of informed consent study has also never been conducted in such a high
stress environment or with such a fragile population. These
changes in environmental stress and potential harm to the
patient may be more salient when making decisions related
to decision making regarding research participation. Further,
participants had already agreed to participate in a study
of informed consent which likely impacted their thought
processes surrounding drug trial participation which is also
likely to play a contributory role in current findings. Overall,
however, the HCP’s endorsement not affecting participant
enrollment is a positive outcome and consistent with the
ultimate goals of the informed consent process.
No relationship was found between the type of HCP
presenting trial information and a surrogate’s decision to participate. This indicates that a physician presenting the RCT
to the surrogate did not reliably predict trial participation
over another type of HCP presenting the same information.
This implies that one type of clinician does not have more
persuasive power than another, regardless of rank and role
in the child’s care. This has important implications for the
informed consent process and supports the ultimate goal of
this construct, protecting the patient. If a given individual had
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more persuasive power in these acutely stressful situations,
they could more easily manipulate the outcome [31, 32].
This would present a significant conflict of interest within
clinical practice, which could become especially problematic
if the presenting clinician was a primary investigator for the
trial desiring to recruit participants. The possible conflict of
interest would have the potential to compromise patient care
and the best interests of the child. However, as this study has
revealed, the type of HCP presenting does not impact the
resultant decision to participate. It therefore appears that this
aspect of protection of human subjects is not compromised.
The third hypothesis examined the relationship between
clinician mention of the institution sponsoring the RCT and
participation. The results indicated that the mention of the
institution supporting the trial reliably distinguished between
surrogates enrolling their child in the experimental protocol
from those surrogates who did not enroll their child. While
this predictive relationship was significant, the direction
of the relationship was unexpected. Specifically, analyses
revealed that when the institution was mentioned, surrogates
were less likely to enroll their child in the experimental
protocol. This finding suggests that mention of the supporting
institution may remind the surrogate of the experimental
nature of the protocol, leading to a lower participation rate.
Previous research has clearly shown a deficit in patient
knowledge regarding RCTs during enrollment [14, 33]. However, giving particular information about the sponsoring
institution may lead surrogates to feel the research is in
the best interests of the institution versus the best interests
of current or future patients. This approach may seem less
personal to the surrogates and perhaps leads to the lower
likelihood of participation.
A few limitations of this study are noted. First, a small
yet clinically significant sample was used to test hypotheses.
Second, the applicability of results to other surrogates may
be limited given parents in the PICU are significantly more
stressed and more prone to symptoms of posttraumatic stress
than parents with children on other hospital services [32].
Nevertheless, this is an important population to study, particularly because of the unique and stressful circumstances of
the PICU. Third, there may be other relevant factors that may
affect the decision-making process which were not addressed
in the study; however, the goal was to address particular
factors that would be relevant across sites and populations.
Finally, the education level and SES measures were likely
not sufficiently sensitive as categories were notably broad.
Additional control of these variables may be informative in
future studies. The study also showcases strengths as multiple
informants were used whenever possible, nonmodifiable
participant characteristics were considered as relevant covariates, and findings represent a contribution to a clinically
significant body of literature surrounding decision making in
a unique environment.
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a role in treatment decisions made by their patients’ families
in the pediatric intensive care unit. However, this influence
is reduced in the context of recruitment in clinical trials
in the PICU, which is consistent with ethical standards
related to the consenting process. In addition, type of HCP
is not related to the decision making process, which also
highlights the equity in the decision-making process and
adherence to ethical standards. Nevertheless, there are subtle
communication factors that play a role in this process. For
instance, participants may possibly feel deceived or pressured
when the sponsoring institution is mentioned or strong
recommendations to participate are given. As any kind of
pressure to participate is counter to the informed consent
process, such techniques should be strongly discouraged and
avoided. The current study indicates that subtleties of HCP
communication merit further investigation regarding their
influence on participation in a pediatric RCT. It also suggests
that the age of the child is likely a significant factor in
this decision making process. The influence of these subtle
factors on decision making as well as the impact of direct
recommendations should be evaluated in more depth and
with additional participants in future studies. Further, the
significant HCP influences may not only play a role in the
high stress environment of the PICU, but also play a role in
other areas of pediatrics. Expansion of the current study to
other pediatric populations (e.g., those with chronic illnesses)
would represent a significant contribution to the literature
related to decision making in RCTs beyond the informed
consent process to ensure protection for these vulnerable
populations.
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